iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event

Company’s President and incoming CEO to participate in a panel
discussion titled “Med Tech / Digital Tools: What’s the Mindset for 2022?” on
January 5, 2022 at 2:00 pm ET

NASHUA, N.H.,
Dec. 23, 2021 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced that it will attend the 11th Annual LifeSci Partners
Corporate Access Event, being held virtually from January 5th to
7th, 2022.

Stacey
Stevens, President and incoming CEO of iCAD, will participate in a panel
discussion titled “Med Tech / Digital Tools: What’s the Mindset for 2022?” on
Wednesday, January 5th at 2:00 pm ET.

Please
register for the event and confirm your interest in meeting with iCAD
management here.

The LifeSci
Corporate Access Event will feature innovative privately held and publicly
traded biotechnology, medical technology, pharmaceutical, life sciences, and
digital health companies from across the globe. The event will include meetings
with company senior management teams and panel discussions featuring KOLs,
CEOs, specialized investors, and healthcare experts, highlighting the most
relevant topics impacting today’s life sciences industry.

About
iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader
providing innovative cancer detection and therapy solutions. For more
information, visit www.icadmed.com.

Contact:

Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com

Investor Relations:
Brian Ritchie, LifeSci Advisors
+ 1-212-915-2578
britchie@lifesciadvisors.com